

# AI-Driven Drug Discovery and Clinical Decision Support: Transforming Modern Therapeutics

Stiven Cardelin Marien MANGALA<sup>1</sup>, Narcisse MALANDA<sup>2</sup>, Stanislas Kevin MBEKE<sup>2</sup>

<sup>1</sup>Higher National Polytechnic School, Mechanics, Energy and Engineering Laboratory, Marien Ngouabi University, BP 69, Brazzaville, Republic of Congo

<sup>2</sup>Dénis SASSOU NGUESSO University –Kintélé, Republic of Congo

## ABSTRACT

Artificial Intelligence (AI) has revolutionized drug discovery and clinical decision-making by enabling high-throughput data analysis, predictive modeling, and personalized therapy. Traditional drug discovery is costly, time-consuming, and often inefficient, while AI-driven approaches significantly reduce time-to-market and improve clinical trial design. This review explores AI applications in drug discovery, clinical decision support systems (CDSS), adverse drug reaction prediction, and personalized medicine, highlighting challenges, ethical considerations, and future perspectives.

**Keywords:** Artificial Intelligence, Drug Discovery, Clinical Decision Support, Predictive Analytics, Personalized Medicine, Pharmacotherapy

## 1. Introduction

The conventional drug discovery pipeline involves target identification, lead optimization, preclinical studies, and clinical trials, which often span over a decade and cost billions of dollars. Despite technological advances, the attrition rate remains high. AI offers a transformative solution by processing large datasets from genomics, proteomics, electronic health records (EHRs), and real-world evidence. Clinical Decision Support Systems (CDSS) integrate AI algorithms to provide clinicians with data-driven recommendations for drug selection, dosing, and monitoring. These systems enhance accuracy, reduce human error, and improve patient outcomes.

## 2. Literature Review

Recent studies demonstrate AI applications across multiple domains:

- **Drug target identification:** Machine learning models analyze genetic and proteomic data to identify potential therapeutic targets.
- **Lead compound optimization:** AI predicts compound efficacy, toxicity, and pharmacokinetics.
- **Clinical trial design:** AI aids patient selection, stratification, and adaptive trial designs.
- **Predictive safety monitoring:** AI-based algorithms identify high-risk patients for adverse drug reactions.

Examples include IBM Watson for drug discovery, Atomwise for virtual screening, and DeepMind's protein structure prediction models.

## 3. Methodology

This narrative review examined peer-reviewed articles from PubMed, Scopus, and Web of Science (2015–2025). Keywords included “AI drug discovery,” “clinical decision support,” “predictive analytics in pharmacology,” and “machine learning drug therapy.”

Data from clinical trials, case studies, and FDA-approved AI-driven tools were analyzed.

## 4. AI Applications in Drug Discovery

### 4.1 Target Identification and Validation

AI models analyze omics data and disease phenotypes to identify therapeutic targets. This reduces experimental validation time and improves success rates.

#### 4.2 Lead Compound Screening

Deep learning algorithms predict binding affinity and toxicity, allowing virtual high-throughput screening.

#### 4.3 Drug Repurposing

AI can identify new indications for approved drugs, reducing development costs and time.

#### 4.4 Clinical Trial Optimization

AI predicts patient response and stratifies populations for adaptive trial designs, improving efficiency.

### 5. Clinical Decision Support Systems (CDSS)

#### 5.1 Personalized Therapy

AI integrates patient data (genomics, comorbidities, lab results) to provide tailored drug recommendations.

#### 5.2 Adverse Drug Reaction Prediction

Machine learning models analyze EHRs to predict potential ADRs before clinical manifestation.

#### 5.3 Workflow Integration

CDSS streamline prescribing practices, automate dosage calculations, and alert clinicians to interactions.

### 6. Challenges

- **Data privacy:** Sensitive patient information requires robust protection.
- **Algorithm transparency:** Black-box AI models may reduce clinician trust.
- **Regulatory barriers:** FDA approval and validation of AI-driven systems remain complex.
- **Integration with clinical workflows:** Systems must complement, not replace, human expertise.

### 7. Future Perspectives

- Integration of AI with wearable devices for real-time drug monitoring
- AI-assisted pharmacogenomics for truly personalized medicine
- Blockchain-based secure EHRs to facilitate AI integration
- Global collaboration for AI-driven drug development

### 8. Conclusion

AI-driven drug discovery and clinical decision support systems are transforming modern therapeutics by improving efficiency, accuracy, and personalization. Despite challenges, ongoing technological, regulatory, and clinical advancements indicate a promising future for AI-assisted pharmacotherapy.

### References

- [1]. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine*, 25(1), 44–56.
- [2]. Vamathevan, J., et al. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery*, 18(6), 463–477.
- [3]. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. *Drug Discovery Today*, 23(6), 1241–1250.
- [4]. Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2020). Drug discovery with explainable AI. *Nature Machine Intelligence*, 2(10), 573–584.
- [5]. Zhavoronkov, A., et al. (2019). Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. *Molecular Pharmaceutics*, 16(10), 1–14.
- [6]. Mak, K.-K., & Pichika, M. R. (2019). Artificial intelligence in drug development: Present status and future prospects. *Drug Discovery Today*, 24(3), 773–780.

- [7]. Wang, F., Casalino, L. P., & Khullar, D. (2019). Deep learning in medicine. *JAMA*, 322(11), 1103–1104.
- [8]. Lavecchia, A. (2019). Deep learning in drug discovery: Opportunities, challenges and future prospects. *Drug Discovery Today*, 24(10), 2017–2032.
- [9]. Esteva, A., et al. (2019). A guide to deep learning in healthcare. *Nature Medicine*, 25, 24–29.
- [10]. Bender, A., & Cortés-Ciriano, I. (2021). Artificial intelligence in drug discovery: What is realistic, what are illusions? Part 1: Chemical and biological data. *Drug Discovery Today*, 26(1), 511–524.